AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics ...

Two A+ stocks investors should consider are Alphabet (GOOG) and AbbVie (ABBV). Alphabet is the top mega-cap stock. It posted ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.

Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. AbbVie beat Wall Street's top- and bottom-line estimates. President Trump told attendees at the National Republican ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

AbbVie Inc. (NYSE:ABBV) reported an earnings per share (EPS) of $2.46, beating the estimated $2.38 and marking a 2.93% ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants. The pharmaceutical company, whose ...